title: Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
abstract: We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
authors: Department of Medical Oncology, Spedali Civili di Brescia, Brescia, Italy. franzval@yahoo.it
authors: Francesca
authors: F
authors: Valcamonico
authors: Vittorio
authors: V
authors: Ferrari
authors: Vito
authors: V
authors: Amoroso
authors: Giovanni
authors: G
authors: Rangoni
authors: Edda
authors: E
authors: Simoncini
authors: Patrizia
authors: P
authors: Marpicati
authors: Lucia
authors: L
authors: Vassalli
authors: Salvatore
authors: S
authors: Grisanti
authors: Giovanni
authors: G
authors: Marini
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib